4 Hrs
Source:
برلمان.كوم
_1777011671128_85597701.png&w=64&q=75){kind=small}
Source: برلمان.كوم
4 Hrsبرلمان.كوم
Source: برلمان.كوم
4 HrsReady to play
Ready to play
A study by University of Michigan researchers found that sotagliflozin suppressed platelet activation in healthy people and people with type 2 diabetes, with a stronger effect than empagliflozin. It reduced clot formation in mice by 60%, compared with 5% to 10% for the comparator drug. Removing the SGLT1 protein from mouse platelets also reduced clot formation by 40%. However, these findings come from laboratory and animal studies and do not prove that the drug prevents heart attacks or strokes in humans, so further clinical studies are needed.
Notice: This Is an AI-Generated Summary
Comments (0)